Coherus Oncology (CHRS) EBIT Margin (2013 - 2026)
Coherus Oncology's (CHRS) quarterly EBIT Margin came in at 225.98% in Q2 2026, up 21761.0% year-over-year from N/an in Q2 2025, and up 23.05% quarter-over-quarter from 293.67% in Q1 2026.
Powered by 
Analysis
Coherus Oncology (CHRS) EBIT Margin (2013 - 2026) Analysis & Trends
Coherus Oncology has disclosed EBIT Margin across 13 years of filings, most recently posting 225.98% for Q2 2026.
- In Q2 2026, EBIT Margin rose 21761.0% year-over-year to 225.98%; the TTM figure through Jun 2026 stood at 311.56% (up 26737.0% YoY), while the FY2025 annual figure was 429.51%, up 32706.0% from the prior year.
- EBIT Margin came in at 225.98% for Q2 2026 at Coherus Oncology, up from 293.67% in the prior quarter.
- In the past five years, EBIT Margin ranged from a high of 42.92% in Q3 2023 to a low of 2937.05% in Q1 2024.
- Average EBIT Margin over 5 years is 437.31%, with a median of 259.83% recorded in 2026.
- Year-over-year, EBIT Margin slumped 272819 bps in 2024 and soared 233914 bps in 2025.
- Over 5 years, EBIT Margin stood at 113.54% in 2022, then soared by 34 bps to 75.29% in 2023, then tumbled by 680 bps to 586.89% in 2024, then surged by 39 bps to 359.9% in 2025, then soared by 37 bps to 225.98% in 2026.
- Per Business Quant data, the three most recent EBIT Margin figures were 225.98% in Q2 2026, 293.67% in Q1 2026, and 359.9% in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 34.95% |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | -133.21% |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 37.40% |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 30.15% |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 32.54% |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | -562.07% |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 17.93% |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | -23.56% |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | -25,380.93% |
| 10 | Coherus Oncology | 209.00 Mn | 103.70 Mn | 10.07 Mn | -225.98% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -225.98% |
| Mar 31, 2026 | -293.67% |
| Dec 31, 2025 | -359.90% |
| Sep 30, 2025 | -383.14% |
| Jun 30, 2025 | -443.59% |
| Mar 31, 2025 | -597.91% |
| Dec 31, 2024 | -586.89% |
| Sep 30, 2024 | -774.22% |
| Jun 30, 2024 | -384.87% |
| Mar 31, 2024 | -2,937.05% |
| Dec 31, 2023 | -75.29% |
| Sep 30, 2023 | -42.92% |
| Jun 30, 2023 | -58.83% |
| Mar 31, 2023 | -208.86% |
| Dec 31, 2022 | -113.54% |
| Sep 30, 2022 | -177.11% |
| Jun 30, 2022 | -73.17% |
| Mar 31, 2022 | -134.62% |
| Dec 31, 2021 | -53.91% |
| Sep 30, 2021 | -39.74% |